![](/wp-content/uploads/2018/10/1o1cRnR1JnM92myeSmA8.png)
$599
Merck’s Januvia Receives CRL from FDA for TECOS
Merck has announced it received a complete response letter (CRL) regarding its submission of data from the TECOS cardiovascular outcomes trial for Januvia (sitagliptin). The company has not disclosed the reason for the CRL, but said it is working with FDA to discuss next steps.